Squibb’s revenge?
Executive Summary
The rumored acquisition of Bristol-Myers Squibb by GlaxoSmithKline would be the latest and largest ripple effect from the Bristol/Squibb integration in 1989. The two CEOs who drove the Glaxo/SmithKline merger at the end of the 1990s (Glaxo's Richard Sykes and SmithKline's Jan Leschly) were both former Squibb execs who learned firsthand the perils of a lack of scale during a period of consolidation. While both Sykes and Leschly have retired, the logic and momentum behind the strategy they pursued is a prime factor driving GSK's interest in Bristol...
You may also be interested in...
QUOTED. 19 April 2021. Jeff Shuren & William Maisel
Two top officials in the US FDA’s device center are warning of delays in the agency’s review of submissions for new products that aren’t directly tied to the coronavirus pandemic.
Breakthrough Therapy Designations At US FDA Stay Sluggish In 2021
With 12 new BTDs announced so far this year, 2021 is on pace to match the COVID-19-depressed total number of designations in 2020. Here’s a breakdown of the candidates that have received the designation.
Half Of US FDA’s Breakthrough Therapy Designations Have Resulted In Approval
Popular expedited review program results in a higher approval rate than the related fast track designation, but the COVID-19 era is seeing a drop in designations and a rise in complete response letters for BTD programs.